Exagen Inc. (XGN) stock
XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.76−0.01 (-0.27%)
Close on Nov 17, 2026Market cap $91.09MP/E –Yield –
Exagen total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Exagen's total debt was $22.84M at Jun 30, 2026. For fiscal 2025 it was $22.91M, up 13.1% from the year before. The highest annual figure on record is $28.97M in fiscal 2022.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.91M | +13.1% |
| FY2024 | Dec 31, 2024 | $20.25M | +3.8% |
| FY2023 | Dec 31, 2023 | $19.50M | -32.7% |
| FY2022 | Dec 31, 2022 | $28.97M | +5.4% |
| FY2021 | Dec 31, 2021 | $27.48M | +3.1% |
| FY2020 | Dec 31, 2020 | $26.66M | +3.1% |
| FY2019 | Dec 31, 2019 | $25.85M | +5.0% |
| FY2018 | Dec 31, 2018 | $24.62M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.84M | -0.6% |
| Q1 FY2026 | Mar 31, 2026 | $22.87M | +9.2% |
| Q4 FY2025 | Dec 31, 2025 | $22.91M | +13.1% |
| Q3 FY2025 | Sep 30, 2025 | $22.94M | +13.3% |
| Q2 FY2025 | Jun 30, 2025 | $22.98M | +13.4% |
| Q1 FY2025 | Mar 31, 2025 | $20.94M | +7.2% |
| Q4 FY2024 | Dec 31, 2024 | $20.25M | +3.8% |
| Q3 FY2024 | Sep 30, 2024 | $20.25M | +4.1% |
| Q2 FY2024 | Jun 30, 2024 | $20.25M | +4.3% |
| Q1 FY2024 | Mar 31, 2024 | $19.54M | -33.4% |
| Q4 FY2023 | Dec 31, 2023 | $19.50M | -32.7% |
| Q3 FY2023 | Sep 30, 2023 | $19.45M | -30.5% |
| Q2 FY2023 | Jun 30, 2023 | $19.41M | -30.3% |
| Q1 FY2023 | Mar 31, 2023 | $29.35M | +6.1% |
| Q4 FY2022 | Dec 31, 2022 | $28.97M | +5.4% |
| Q3 FY2022 | Sep 30, 2022 | $28.01M | +2.6% |
| Q2 FY2022 | Jun 30, 2022 | $27.83M | +2.8% |
| Q1 FY2022 | Mar 31, 2022 | $27.65M | +2.9% |
| Q4 FY2021 | Dec 31, 2021 | $27.48M | +3.1% |
| Q3 FY2021 | Sep 30, 2021 | $27.29M | +3.2% |
| Q2 FY2021 | Jun 30, 2021 | $27.07M | +3.1% |
| Q1 FY2021 | Mar 31, 2021 | $26.86M | +3.1% |
| Q4 FY2020 | Dec 31, 2020 | $26.66M | +3.1% |
| Q3 FY2020 | Sep 30, 2020 | $26.45M | +3.0% |
| Q2 FY2020 | Jun 30, 2020 | $26.25M | +6.6% |
| Q1 FY2020 | Mar 31, 2020 | $26.05M | – |
| Q4 FY2019 | Dec 31, 2019 | $25.85M | – |
| Q3 FY2019 | Sep 30, 2019 | $25.68M | – |
| Q4 FY2018 | Dec 31, 2018 | $24.62M | – |
See a number that looks wrong?